Marker Therapeutics, Inc.
Key Metrics
Market Snapshot
About
Clinical-stage immuno-oncology company developing T cell-based therapies to treat hematologic malignancies and solid tumors. Lead programs utilize multi-targeted autologous tumor infiltrating lymphocytes (TIL) designed to recognize and kill cancer cells with multiple antigens. Focus on accessible off-the-shelf solutions.